Is Azithromycin the First-Choice Macrolide for Treatment of Community-Acquired Pneumonia?

Sánchez, F.; Mensa, J.; Martínez, J.A.; Garcia, E.; Marco, F.; González, J.; Marcos, M.A.; Soriano, A.; Torres, A.
May 2003
Clinical Infectious Diseases;5/15/2003, Vol. 36 Issue 10, p1239
Academic Journal
Combination treatment with a β-lactam plus a macrolide may improve the outcome for elderly patients with community-acquired pneumonia (CAP). The prognoses and mortality rates for elderly patients with CAP who receive ceftriaxone combined with a 3-day course of azithromycin or a 10-day course of clarithromycin were compared in an open-label, prospective study. Of 896 assessable patients, 220 received clarithromycin and 383 received azithromycin. There were no significant differences between groups with regard to the severity score defined by the Pneumonia Patient Outcomes Research Team (PORT) study group; the incidence of bacteremia was also not significantly different. However, for patients treated with azithromycin, the length of hospital stay was shorter (mean ± SD, 7.4 ± 5 vs. 9.4 ± 7 days; P < .01) and the mortality rate was lower (3.6% vs. 7.2%;P < .05), compared with those treated with clarithromycin. There might be a difference in the outcome for patients with CAP depending on the macrolide used. A shorter treatment course with azithromycin may result in better compliance with therapy.


Related Articles

  • Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Gaynor, B.D.; Holbrook, K.A.; Whitcher, J.P.; Holm, S.O.; Jha, H.C.; Chaudhary, J.S.P.; Bhatta, R.C.; Lietman, T. // British Journal of Ophthalmology;Feb2003, Vol. 87 Issue 2, p147 

    Aims: To determine if macrolide resistant Streptococcus pneumoniae will be a major concern in areas that receive annual mass azithromycin distributions for trachoma. Methods: A cross sectional survey was conducted of nasopharyngeal S pneumoniae isolates for susceptibility to azithromycin 1 year...

  • Azithromycin/clarithromycin.  // Reactions Weekly;6/22/2013, Issue 1458, p10 

    The article describes the cases of two children who developed macrolide resistance during treatment with azithromycin and clarithromycin for a Mycoplasma pneumoniae infection.

  • Azithromycin pros beat cons in pneumonia.  // Clinical Advisor;Jul2014, Vol. 17 Issue 7, p15 

    No abstract available.

  • Electron microscopic structures, serum resistance, and plasmid restructuring of New Delhi metallo-β-lactamase-1 (NDM-1)-producing ST42 Klebsiella pneumoniae emerging in Japan. Yamamoto, Tatsuo; Takano, Tomomi; Fusegawa, Takehito; Shibuya, Tetsuo; Hung, Wei-Chun; Higuchi, Wataru; Iwao, Yasuhisa; Khokhlova, Olga; Reva, Ivan // Journal of Infection & Chemotherapy (Springer Science & Business;Feb2013, Vol. 19 Issue 1, p118 

    Enterobacteriaceae, carrying the New Delhi metallo-β-lactamase-1 (NDM-1) gene ( bla), have emerged and posed a threat since 2006. In Japan, bla-carrying Escherichia coli was first described in 2010. In this study, we characterized NDM-1-positive Klebsiella pneumoniae strain 419 in Japan,...

  • Azithromycin for Elderly Patients With Pneumonia. Bin Abdulhak, Aref A.; Khan, Abdur Rahman; Wimmer, Alan P. // JAMA: Journal of the American Medical Association;10/1/2014, Vol. 312 Issue 13, p1352 

    A letter to the editor is presented in response to an article by Eric M. Mortensen and colleagues about the risk of death with azithromycin use in elderly patients with pneumonia, published in the previous issue.

  • Azithromycin for Elderly Patients With Pneumonia. Mortensen, Eric M.; Alvarez, Carlos A.; Halm, Ethan A. // JAMA: Journal of the American Medical Association;10/1/2014, Vol. 312 Issue 13, p1352 

    A response by Eric M. Mortensen and colleagues to a letter to the editor about their article on the risk of death with azithromycin use in elderly patients with pneumonia, published in the previous issue, is presented.

  • Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. Metzler, Kelli; Drlica, Karl; Blondeau, Joseph M. // Journal of Antimicrobial Chemotherapy (JAC);Mar2013, Vol. 68 Issue 3, p631 

    Background Previous work showed a higher prevalence of macrolide/azalide resistance in provinces of Canada where azithromycin was the major treatment for Streptococcus pneumoniae as compared with regions where clarithromycin was the dominant treatment. These data provided a way to test the...

  • Postantibiotic Effect of Levofloxacin Against Pneumococci. Spangler, S.K.; Lin, G.; Jacobs, M.R.; Appelbaum, P.C. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p378 

    Tests the postantibiotic effect (PAE) and PAE-sub-MIC (SME) of levofloxacin, ofloxacin, ciprofloxacin, erythromycin, azithromycin and clarithromycin against several pneumococci. Measurement of the PAE-SME; Exposure to antibiotics.

  • Haloperidol.  // Reactions Weekly;7/7/2007, Issue 1159, p17 

    The article describes the case of a male patient who had developed hypoglycemia after receiving a single dose of haloperidol. He was admitted with community-acquired pneumonia and received ceftriaxone and azithromycin. Laboratory results of the patient upon admission is presented. The patient...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics